scholarly journals Safety and Efficacy of a New Posterior Chamber Phakic Intraocular Lens in Cases of High Myopia: Early Results

2020 ◽  
Vol Volume 14 ◽  
pp. 3681-3689
Author(s):  
Praveen Subudhi ◽  
Sweta Patro ◽  
Prateek Agarwal ◽  
Zahiruddin Khan ◽  
B Nageswar Rao Subudhi ◽  
...  
Keyword(s):  
Intraocular Lens ◽  
High Myopia ◽  
Posterior Chamber ◽  
Phakic Intraocular Lens ◽  
Safety And Efficacy ◽  
Early Results

scholarly journals Early Results with a New Posterior Chamber Phakic Intraocular Lens in Patients with High Myopia

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Dilek Yaşa ◽  
Ufuk Ürdem ◽  
Alper Ağca ◽  
Yusuf Yildirim ◽  
Burçin Kepez Yildiz ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Endothelial Cell ◽  
Intraocular Lens ◽  
High Myopia ◽  
Posterior Chamber ◽  
Phakic Intraocular Lens ◽  
Phakic Iol ◽  
Distance Visual Acuity ◽  
Early Results ◽  
Manifest Refraction

Purpose. To report clinical results of a foldable, hydrophilic acrylic, single-piece, injectable, posterior chamber phakic intraocular lens (pIOL).Material and Methods. Medical records of patients who underwent posterior chamber phakic IOL (Eyecryl Phakic IOL, Biotech Vision Care, Ahmedabad, India) implantation for surgical correction of myopia were retrospectively reviewed. Only patients with at least a one-year follow-up were included. Manifest refraction, uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), endothelial cell density (ECD), and pIOL vault were analyzed at 1, 3, 6, and 12 months after surgery. Complications observed during and after surgery were also recorded.Results. The study included 58 eyes of 29 patients. Mean patient age was 32 ± 7 years. Spherical equivalent of manifest refraction was −13.41 ± 3.23 D preoperatively and −0.44 ± 0.55 D postoperatively. Preoperative CDVA was 0.29 ± 0.71 logMAR. Postoperative UDVA and CDVA were 0.21 ± 0.66 and 0.15 ± 0.69 logMAR, respectively, at the 12-month visit. At the 12-month visit, the efficacy index was 1.20 and the safety index was 1.39. Mean ECD was 2713 ± 339 cells/mm2at the preoperative visit and 2608 ± 362 cells/mm2at the 12-month visit (3.9% loss,p<0.001). ECD loss from 3 months to 12 months was not statistically significant. No significant cataract formation, significant endothelial cell loss, glaucoma, uveitis, or any other vision-threatening complication was observed.Conclusion. Based on postoperative experience, we have found that Eyecryl Phakic IOL is safe and effective for treating high myopia.

scholarly journals A study on the safety and efficacy of posterior chamber phakic intraocular lens (refractive implantable lens) in high myopia

2019 ◽  
Vol 57 (2) ◽  
pp. 113
Author(s):  
Sivaviganesh Subramanian ◽  
SharmilaDevi Vadivelu ◽  
MAnanda Babu ◽  
B Meenakshi ◽  
JizMary Santhosh
Keyword(s):  
Intraocular Lens ◽  
High Myopia ◽  
Posterior Chamber ◽  
Phakic Intraocular Lens ◽  
Safety And Efficacy

scholarly journals Posterior chamber collagen copolymer phakic intraocular lens with a central hole for moderate-to-high myopia

Medicine ◽  
2016 ◽  
Vol 95 (36) ◽  
pp. e4641 ◽  
Author(s):  
Xinfang Cao ◽  
Weiliang Wu ◽  
Yang Wang ◽  
Chen Xie ◽  
Jianping Tong ◽  
...  
Keyword(s):  
Intraocular Lens ◽  
High Myopia ◽  
Central Hole ◽  
Posterior Chamber ◽  
Phakic Intraocular Lens
Sign in / Sign up

Export Citation Format

Share Document